Schlagwort: Motif
“Iclaprim addresses a high unmet medical need”
Motif Bio is dedicated to tackling serious and life-threatening bacterial infections with new antibiotics. With an expected read-out of its second phase III pivotal...
“Iclaprim is now eligible for 10 years of market exclusivity”
Motif (LSE:MTFB) is addressing an urgent need for new antibiotics with a large market opportunity. Iclaprim has a unique mode of action, safety and...